References
- ALSUntangled website [online]. Available at: http://www.alsuntangled.com/open.php. Accessed Feburary 14, 2020.
- LEAPXX website [online]. Available at: http://leapxx.com/ingredients. Accessed February 14, 2020.
- LEAPXX website [online]. Available at: https://www.leapxx.com/the-ultimate-guarantee/. Accessed February 20. 2020.
- Facebook page on LEAP2BFIT [online]. Available at: https://www.facebook.com/pg/leap2bfit/reviews/?referrer=page_recommendations_see_all&ref=page_internal. Accessed February 14, 2020.
- Healing ALS Conference page on conference speaker Mark Manchester [online]. Available at: https://healingalsconference.org/speakers/speaker/37-mark-manchester. Accessed February 14, 2020.
- The ALSUntangled Group. ALSUntangled 15. Coconut Oil. Amyotroph Lateral Scler. 2012;13:328–30.
- The ALSUntangled Group. ALSUntangled 44: Curcumin. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19:623–9.
- The ALSUntangled Group. ALSUntangled 53: Carnitine Supplements. Amyotroph Lateral Scler Frontotemporal Degener. 2020 [Epub ahead of print].
- The ALSUntangled Group. ALSUntangled 49 Resveratrol. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20:625–9.
- The ALSUntangled Group. ALSUntangled No. 30: Methylcobalamin. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16:536–9.
- Mengs U, Pohl RT, Mitchell T. Legalon® SIL: The antidote of choice in patients with acute hepatotoxicity from amatoxin poisoning. Cpb. 2012;13:1964–70.
- Abenavoli L, Izzo A, Milic N, Cicala C, Santini A, Capasso R. Milk thistle (Silybum marianum): a concise overview on its chemistry, pharmacological, and nutraceutical uses in liver diseases. Phytother Res. 2018;32:2202–13.
- PatientsLikeMe [online]. Available at: https://www.patientslikeme.com/conditions/als. Accessed January 28, 2019.
- Wei F, Liu S-K, Liu X-Y, Li Z-J, Li B, Zhou Y-L, et al. Meta-analysis: silymarin and its combination therapy for the treatment of chronic hepatitis B. Eur J Clin Microbiol Infect Dis. 2013;32:657–69.
- Yang Z, Zhuang L, Lu Y, Xu Q, Chen X. Effects and Tolerance of silymarin (milk thistle) in chronic hepatitis C virus infection patients: a meta-analysis of randomized controlled trials. Biomed Res Int. 2014;2014:1–9.
- Voroneanu L, Nistor I, Dumea R, Apetrii M, Covic A. Silymarin in type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled Trials. J Diabetes Res. 2016;2016:1–10.
- Kheong C, Mustapha N, Mahadeva S. A Randomized trial of silymarin for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2017;15:1940–9.
- Scapicchio P. Revisiting choline alphoscerate profile: a new, perspective, role in dementia?. Int J Neurosci. 2013;123:444–9.
- Moreno M. Cognitive improvement in mild to moderate alzheimer’s dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial. Clin Ther. 2003;25:178–93.
- Birks J, Harvey R. Donepezil for dementia due to Alzheimer’s disease. Cochrane Database Syst Rev. 2018;6:CD001190
- Tsai R, Boxer A. Treatment of frontotemporal dementia. Curr Treat Options Neurol. 2014;16:319.
- Norris F, Tan Y, Fallat R, Elias L. Trial of oral physostigmine in amyotrophic lateral sclerosis. Clin Pharmacol Ther. 1993;54:680–2.
- Aquilonius S-M, Askmark H, Eckernäs S-Å, Gillberg P-G, Hilton-Brown P, Rydin E, et al. Cholinesterase inhibitors lack therapeutic effect in amyotrophic lateral sclerosis. A controlled study of physostigmine versus neostigmine. Acta Neurol Scand. 1986;73:628–32.
- PatientsLikeMe [online]. Available at: https://www.patientslikeme.com/treatment_evaluations/browse?brand=false&condition_id=9&id=28366. Accessed February 22, 2020.
- Brownawell A, Carmines E, Montesano F. Safety assessment of AGPC as a food ingredient. Food Chem Toxicol. 2011;49:1303–15.
- Maitra I, Marcocci L, Droy-Lefaix M, Packer L. Peroxyl Radical scavenging activity of gingko biloba extract EGb 761. Biochem Pharmacol. 1995;49:1649–55.
- Sastre J, Millan A, de la Asuncion J, Pla R, Juan G, Pallardo F, et al. A Ginkgo Biloba Extract (EGb 761) Prevents Mitochondrial Aging by Protecting Against Oxidative Stress. Free Radic Biol Med. 1998;24:298–304.
- Ellnain-Wojtaszek M, Kruczyński Z, Kasprzak J. Investigation of the free radical scavenging activity of Ginkgo biloba L. leaves. Fitoterapia. 2003;74:1–6.
- Bozzo F, Mirra A, Carri M. Oxidative stress and mitochondrial damage in the pathogenesis of ALS: new perspectives. Neurosci Lett. 2017;636:3–8.
- Ferrante R, Klein A, Dedeoglu A, Beal M. Therapeutic efficacy of EGb761 (Gingko biloba extract) in a transgenic mouse model of amyotrophic lateral sclerosis. J Mol Neurosci. 2001;17:89–96.
- PatientsLikeMe [online]. Available at: https://www.patientslikeme.com/treatment_evaluations/browse?brand=false&condition_id=9&id=120. Accessed February 22, 2020.
- Mei N, Guo X, Ren Z, Kobayashi D, Wada K, Guo L. Review of Ginkgo biloba-induced toxicity, from experimental studies to human case reports. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2017;35:1–28.
- Burk R, Hill K. Regulation of selenium metabolism and transport. Annu Rev Nutr. 2015;35:109–34.
- Steinbrenner H, Sies H. Selenium homeostasis and antioxidant selenoproteins in brain: implications for disorders in the central nervous system. Arch Biochem Biophys. 2013;536:152–7.
- PatientsLikeMe [online]. Available at: https://www.patientslikeme.com/treatment_evaluations/browse?brand=false&condition_id=9&id=151. Accessed February 22, 2020.
- Apostolski S, Marinkovic Z, Nikolic A, Blagojevic D, Spasic M, Michelson A. Glutathione peroxidase in amyotrophic lateral sclerosis: the effects of selenium supplementation. J Environ Pathol Toxicol Oncol. 1998;17:325–9.
- Vinceti M, Filippini T, Del Giovane C, Dennert G, Zwahlen M, Brinkman M, et al. Selenium for preventing cancer (Review). Cochrane Database Syst Rev. 2018;1:CD005195
- Callaghan B, Feldman D, Gruis K, Feldman E. The association of exposure to lead, mercury, and selenium and the development of amyotrophic lateral sclerosis and the epigenetic implications. Neurodegenerative Dis. 2011;8:1–8.
- Vinceti M, Bonvicini F, Rothman K, Vescovi L, Wang F. The relation between amyotrophic lateral sclerosis and inorganic selenium in drinking water: a population-based case-control study. Environ Health. 2010;9:77.
- Peters TL, Beard JD, Umbach DM, Allen K, Keller J, Mariosa D, et al. Blood levels of trace metals and amyotrophic lateral sclerosis. NeuroToxicology. 2016;54:119–26.
- Madrioli J, Michalke B, Solovyev N, Grill P, Violi F, Lunetta C, et al. Elevated levels of selenium species in cerebrospinal fluid of amyotrophic lateral sclerosis patients with disease-associated gene mutations. Neurodegener Dis. 2017;17:171–80.
- Vinceti M, Solovyev N, Mandrioli J, Crespi CM, Bonvicini F, Arcolin E, et al. Cerebrospinal fluid of newly diagnosed amyotrophic lateral sclerosis patients exhibits abnormal levels of selenium species including elevated selenite. NeuroToxicology. 2013;38:25–32.
- Estevez AO, Mueller CL, Morgan KL, Szewczyk NJ, Teece L, Miranda-Vizuete A, et al. Selenium induces cholinergic motor neuron degeneration in Caenorhabditis elegans. NeuroToxicology. 2012;33:1021–32.
- Parton M, Mitsumoto H, Leigh P. Amino acids for amyotrophic lateral sclerosis/motor neuron disease (Review). Cochrane Database Syst Rev. 2003;4:CD003457.
- Smith A, Smith S, de Jager C, Whitbread P, Johnston C, Agacinski G, et al. Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial. PLoS One. 2010;5:e12244.
- Zoccolella S, Bendotti C, Beghi E, Logroscino G. Homocysteine levels and amyotrophic lateral sclerosis: a possible link. Amyotroph Lateral Scler. 2010;11:140–7.
- Eaton L, Woltman W, Butt H. Vitamin E and B6 in the treatment of neuromuscular diseases. Proceedings of the Staff Meetings of the Mayo Clinic. 1941;16:523–8.
- Ferrebee J, Klingman W, Frantz A. Vitamin E and Vitamin B6: clinical experience in the treatment of muscular dystrophy and amyotrophic lateral sclerosis. JAMA. 1941;116:1895–6.
- Zhang X, Chen S, Li L, Wang Q, Le W. Folic acid protects motor neurons against the increased homocysteine, inflammation and apoptosis in SOD1G93A transgenic mice. Neuropharmacology. 2008;54:1112–9.
- Orrell R, Lane R, Ross M. A systematic review of antioxidant treatment for amyotrophic lateral sclerosis/motor neuron disease. Amyotroph Lateral Scler. 2008;9:195–211.
- Ellis T, Cudkowicz M, McKenna-Yasek D, Eggelston P, Brown R, Cros D. Combination antioxidant therapy in amyotrophic lateral sclerosis. Neurology. 1997;48:A127.
- PatientsLikeMe [online]. Available at: https://www.patientslikeme.com/treatment_evaluations/browse?brand=false&condition_id=9&id=29898. Accessed February 22, 2020.
- Facebook [online]. Available at: https://www.facebook.com/pg/MarksMadnessFestival/posts/. Accessed March 9, 2020.
- Personal observation by Richard Bedlack MD PhD.
- Harrison D, Mehta P, van Es MA, Stommel E, Drory VE, Nefussy B, et al. “ALS reversals”: demographics, disease characteristics, treatments, and co-morbidities. Amyotroph Lat Scl Fr. 2018;19:495–9.
- ALS Reversals [online]. Available at: http://www.alsreversals.com/star.html. Accessed February 22, 2020.
- LEAPXX [online]. Available at: https://www.leapxx.com/tips-on-taking-your-leap/. Accessed February 22, 2020.